In this issue:
Post-TKI risks
Association between cardiac toxic effects and therapies
Efficacy and safety of Fol-CHOP
VEN-R2 in MCL patients
Comparing clinicopathological features in MCL patients
Salvage therapies for B-cell lymphomas
Durvalumab plus CAR T-cell therapy
Efficacy of enasidenib
Comparison of molecular target therapies
Safety of oral decitabine plus cedazuridine and venetoclax
Please login below to download this issue (PDF)